IRAK2 and neoplasm: In addition, our data also suggested that the DPG anti-tumor effect is related to nuclear factor kappa B (NF-kB) pathway suppression, where interleukin-1 receptor-associated kinase 2 (IRAK2)- and TNF receptor-associated factor (TRAF6)-mediating microRNA (miR)-16 and miR-146a, respectively, might be a potential therapeutic target of DPG [4].